A Phase 2 interventional study of AT-1501 in Amyotrophic Lateral Sclerosis, sponsored by Anelixis Therapeutics, LLC. Completed at 13 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-28.
Sponsored by Anelixis Therapeutics, LLC · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States — 98 open to participants now, 129 under way, 11 of them phase 3. Amyotrophic Lateral Sclerosis · United States.
Among the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, this one is the 114th largest by enrollment of the 307 interventional ones that give a count, is one of 29 that started in 2020, is one of 89 in phase 2, and was the 261st registered.
980 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 279 are open to participants now.
Browse Amyotrophic Lateral Sclerosis studies →98 of the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States are open now. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 18–80
Cognixion · Sites in United States
Ages 18+
Johns Hopkins University · Sites in United States
Ages 18+ · Healthy volunteers
Neuralink Corp · Sites in United States
Ages 18+
Biogen · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 193 Amyotrophic Lateral Sclerosis studies recruiting now, 118 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 55 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
440 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 89 · Phase 2 139 · Phase 3 48 · Phase 4 1
First in 1982; this study’s year is marked. 29 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 54 is above the median of 38 across 664 interventional studies indexed under Amyotrophic Lateral Sclerosis.
Median enrollment 33 across the 307 interventional studies, 100 across the 121 observational. Of the 277 that completed or were terminated, 102 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
163 of 440 have an industry lead sponsor. The 10 most frequent:
Anelixis Therapeutics, LLC is the lead sponsor of 2 studies on the registry; none are open to participants now.
Anelixis Therapeutics, LLC has 1 study filed under Amyotrophic Lateral Sclerosis — fewer than ten, so there is no comparison to draw.
41 of the studies in Amyotrophic Lateral Sclerosis with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07161999Phase 3Coya TherapeuticsStudy of COYA 302 for the Treatment of ALS | 2027-04 |
| NCT04057898Phase 3MediciNovaEvaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS | 2027-04 |
| NCT04297683Phase 3Merit E. Cudkowicz, MDHEALEY ALS Platform Trial - Master Protocol | 2027-07 |
| NCT07410806Phase 3Merit E. Cudkowicz, MDHEALEY ALS Platform Trial - Regimen I NUZ-001 | 2027-07-01 |
| NCT04220190Phase 3Rapa Therapeutics LLCRAPA-501 Therapy for ALS | 2027-07-01 |
Add all 41 to your calendar (.ics) → With an account.
Among the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 2a, multi-center, open label, multiple dose study of AT-1501, a humanized monoclonal antibody antagonist to CD40 ligand (CD40L). Approximately 54 adults with Amyotrophic Lateral Sclerosis (ALS) will be enrolled into the study in the United States and Canada at approximately 13 ALS treatment sites.
Participants will be enrolled into one of four ascending doses.
This is a Phase 2a, multi-center, open label, multiple dose study of AT-1501, a humanized monoclonal antibody antagonist to CD40L. Approximately 54 adults with ALS will be enrolled into the study in the United States and Canada at approximately 13 ALS treatment sites.
Four ascending doses of AT-1501 will be administered as an IV infusion to sequentially enrolling cohorts. Each participant will receive 6 bi-weekly (every other week) infusions of AT-1501 over an 11-week period.
The study is estimated to take 19 weeks for participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Abnormal function of the immune system resulting from:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
4 sequential dose cohorts
Drug: AT-1501
AT-1501 monoclonal antibody targeting CD40L given as an IV infusion
Safety and Tolerability
Incidence of adverse events (AEs) reported as number of participants with at least one TEAE (Treatment Emergent Adverse Event) and at least one SAE (Serious Adverse Event).
Time frame: Up to 18 Weeks
Safety and Tolerability
Incidence of adverse events (AEs) reported as number of TEAEs (Treatment Emergent Adverse Events) having occurred.
Time frame: Up to 18 Weeks
| Milestone | AT-1501 1.0 mg/kg | AT-1501 2.0 mg/kg | AT-1501 4.0 mg/kg | AT-1501 8.0 mg/kg |
|---|---|---|---|---|
| Started | 9 | 9 | 18 | 18 |
| Completed | 8 | 7 | 18 | 16 |
| Not completed | 1 | 2 | 0 | 2 |
| Withdrew: Adverse event | 1 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 2 |
| Withdrew: Undergoing cancer treatment & was unable to return to site to complete eos visit within window | 0 | 1 | 0 | 0 |
Incidence of adverse events (AEs) reported as number of participants with at least one TEAE (Treatment Emergent Adverse Event) and at least one SAE (Serious Adverse Event).
| participants | AT-1501 1.0 mg/kg | AT-1501 2.0 mg/kg | AT-1501 4.0 mg/kg | AT-1501 8.0 mg/kg |
|---|---|---|---|---|
| Number of Subjects with at Least One TEAE | 8 | 8 | 10 | 16 |
| Number of Subjects with at Least One SAE | 0 | 1 | 0 | 0 |
Incidence of adverse events (AEs) reported as number of TEAEs (Treatment Emergent Adverse Events) having occurred.
| TEAEs | AT-1501 1.0 mg/kg | AT-1501 2.0 mg/kg | AT-1501 4.0 mg/kg | AT-1501 8.0 mg/kg |
|---|---|---|---|---|
| Safety and Tolerability | 30 | 66 | 54 | 67 |
Collected over All serious adverse events were collected from the time of informed consent to 4 weeks after a patient's last dose of investigational product. All adverse events were collected from the first administration of investigational product until completion of the final visit, up to 15 weeks.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AT-1501 1.0 mg/kg | 0/9 (0%) | 0/9 (0%) | 8/9 (88.9%) |
| AT-1501 2.0 mg/kg | 0/9 (0%) | 1/9 (11.1%) | 8/9 (88.9%) |
| AT-1501 4.0 mg/kg | 0/18 (0%) | 0/18 (0%) | 10/18 (55.6%) |
| AT-1501 8.0 mg/kg | 0/18 (0%) | 0/18 (0%) | 16/18 (88.9%) |
| Event | AT-1501 1.0 mg/kg | AT-1501 2.0 mg/kg | AT-1501 4.0 mg/kg | AT-1501 8.0 mg/kg |
|---|---|---|---|---|
| Tonsil cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/9 | 1/9 | 0/18 | 0/18 |
| Event | AT-1501 1.0 mg/kg | AT-1501 2.0 mg/kg | AT-1501 4.0 mg/kg | AT-1501 8.0 mg/kg |
|---|---|---|---|---|
| FatigueGeneral disorders | 4/9 | 3/9 | 0/18 | 7/18 |
| HeadacheNervous system disorders | 3/9 | 2/9 | 3/18 | 3/18 |
| FallInjury, poisoning and procedural complications | 0/9 | 3/9 | 5/18 | 4/18 |
| DizzinessNervous system disorders | 2/9 | 1/9 | 1/18 | 1/18 |
| HypoaesthesiaNervous system disorders | 1/9 | 2/9 | 0/18 | 0/18 |
| Peripheral swellingGeneral disorders | 0/9 | 2/9 | 0/18 | 0/18 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 2/9 | 2/9 | 0/18 | 2/18 |
| Musculoskeletal stiffnessMusculoskeletal and connective tissue disorders | 2/9 | 1/9 | 0/18 | 0/18 |
| Neck painMusculoskeletal and connective tissue disorders | 1/9 | 2/9 | 0/18 | 0/18 |
| DepressionPsychiatric disorders | 2/9 | 1/9 | 0/18 | 1/18 |
| Age, Categorical(Participants) | AT-1501 1.0 mg/kg | AT-1501 2.0 mg/kg | AT-1501 4.0 mg/kg | AT-1501 8.0 mg/kg | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 7 | 6 | 15 | 11 | 39 |
| >=65 years | 2 | 3 | 3 | 7 | 15 |
| Age, Continuous(years) | AT-1501 1.0 mg/kg | AT-1501 2.0 mg/kg | AT-1501 4.0 mg/kg | AT-1501 8.0 mg/kg | Total |
|---|---|---|---|---|---|
| Mean | 61.2 ± 6.5 | 59 ± 14.76 | 56.4 ± 8.53 | 60.3 ± 11.11 | 59 ± 10.29 |
| Sex: Female, Male(Participants) | AT-1501 1.0 mg/kg | AT-1501 2.0 mg/kg | AT-1501 4.0 mg/kg | AT-1501 8.0 mg/kg | Total |
|---|---|---|---|---|---|
| Female | 3 | 2 | 6 | 8 | 19 |
| Male | 6 | 7 | 12 | 10 | 35 |
| Ethnicity (NIH/OMB)(Participants) | AT-1501 1.0 mg/kg | AT-1501 2.0 mg/kg | AT-1501 4.0 mg/kg | AT-1501 8.0 mg/kg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 3 | 3 |
| Not Hispanic or Latino | 9 | 9 | 18 | 15 | 51 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | AT-1501 1.0 mg/kg | AT-1501 2.0 mg/kg | AT-1501 4.0 mg/kg | AT-1501 8.0 mg/kg | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 9 | 8 | 17 | 18 | 52 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| ALSFRS-R Total Score at Screening(units on a scale) | AT-1501 1.0 mg/kg | AT-1501 2.0 mg/kg | AT-1501 4.0 mg/kg | AT-1501 8.0 mg/kg | Total |
|---|---|---|---|---|---|
| Mean | 41.1 ± 3.02 | 40.2 ± 1.92 | 39.7 ± 3.69 | 39.2 ± 2.65 | 39.9 ± 3.0 |
| ALSFRS-R Subdomain at Screening(units on a scale) | AT-1501 1.0 mg/kg | AT-1501 2.0 mg/kg | AT-1501 4.0 mg/kg | AT-1501 8.0 mg/kg | Total |
|---|---|---|---|---|---|
| Dyspnea | 4 ± 0 | 3.8 ± 0.44 | 3.7 ± 0.59 | 3.8 ± 0.43 | 3.8 ± 0.46 |
| Orthopnea | 4.0 ± 0 | 3.8 ± 0.67 | 3.9 ± 0.32 | 3.9 ± 0.24 | 3.9 ± 0.35 |
| Respiratory Insufficiency | 4.0 ± 0 | 4.0 ± 0 | 3.9 ± 0.47 | 3.7 ± 0.57 | 3.9 ± 0.44 |
| ALSFRS-R Total Score at Baseline(units on a scale) | AT-1501 1.0 mg/kg | AT-1501 2.0 mg/kg | AT-1501 4.0 mg/kg | AT-1501 8.0 mg/kg | Total |
|---|---|---|---|---|---|
| Mean | 40.4 ± 3.17 | 40.0 ± 2.0 | 39.6 ± 3.99 | 38.6 ± 3.96 | 39.5 ± 3.56 |
3 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2020 to primary completion in Mar 2022, 17 months.
Results were first posted in Jun 2023, 1 year 3 months after primary completion.
Of 36 industry-sponsored phase 2 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 35. This study's 17 months is below that.
Counting every sponsor, half of 73 studies reached it within 24 months; a quarter within 16 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tegoprubart
Amyotrophic Lateral Sclerosis →
Anelixis Therapeutics, LLC